{
    "nct_id": "NCT03900949",
    "official_title": "A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia",
    "inclusion_criteria": "* Ability to understand and the willingness to sign a written informed consent document\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Newly diagnosed AML as confirmed by bone marrow and/or peripheral blood examination as indicated, with:\n\n  * Confirmed CD33 positivity, per institutional standards\n  * Presence of FLT3 internal tandem duplication (ITD) or tyrosine kinase domain (TKD) mutation as confirmed by next-generation sequencing (NGS) or other molecular method\n* Aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN; local laboratory)\n* Alanine aminotransferase (ALT) < 2.5 x ULN\n* Total bilirubin < 2 x ULN (except for patients with known Gilbert's syndrome)\n* Calculated creatinine clearance (according to the Cockcroft-Gault equation) > 40 mL/min OR serum creatinine < 1.5 x the ULN\n* Female patients of childbearing potential must agree to use adequate contraception (2 forms of contraception or abstinence) from the screening visit until 6 months following the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Male patients of childbearing potential having intercourse with females of childbearing potential must agree to abstain from heterosexual intercourse or have their partner use 2 forms of contraception from the screening visit until 4 months following the last dose of study treatment. They must also refrain from sperm donation from the screening visit until 4 months following the last dose of study treatment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement to enter study)\n* Acute promyelocytic leukemia (per World Health Organization classification)\n* Active central nervous system (CNS) involvement by AML, as assessed at discretion of principal investigator (PI) or treating physician and confirmed by lumbar puncture\n* Except for hydroxyurea, no other prior systemic anti-AML therapies may have been received prior to starting study therapy\n* Known history of veno-occlusive disease\n* Known active human immunodeficiency virus (HIV), active hepatitis B or active hepatitis C infection\n* Patients with the following will be excluded: uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmia, myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled ventricular arrhythmias\n* Patients with uncontrolled infection will not be enrolled until infection is treated\n* Any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the patient or compliance with the protocol\n* Inability to take oral medication\n* Hypersensitivity to any study agent, or its excipients, when administered alone\n* Pregnancy or breastfeeding at the time of enrollment",
    "miscellaneous_criteria": ""
}